81 related articles for article (PubMed ID: 29262889)
21. [WT1 gene expression in leukemia patients and its correlation with prognosis and multidrug resistance].
Guo X; Xu S; Dong Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Feb; 20(2):69-72. PubMed ID: 11601201
[TBL] [Abstract][Full Text] [Related]
22. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
25. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
[TBL] [Abstract][Full Text] [Related]
26. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
27. [Expression and Significance of PTEN and BCL-2 in Acute Myeloid Leukemia].
Sun JY; Mu N; Mu J; Li W; Zhang CG; Wang DM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):121-125. PubMed ID: 29397829
[TBL] [Abstract][Full Text] [Related]
28. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
[TBL] [Abstract][Full Text] [Related]
29. The influence of Bcl-2 and myeloid antigen expression on response to therapy in childhood acute lymphoblastic leukemia.
Amirghofran Z; Daneshbod Y; Gholijani N; Esmaeilbeig M
Arch Iran Med; 2011 May; 14(3):170-4. PubMed ID: 21529104
[TBL] [Abstract][Full Text] [Related]
30. [Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia].
Wen C; Ma FT; Wan WQ
Zhongguo Dang Dai Er Ke Za Zhi; 2010 Mar; 12(3):177-80. PubMed ID: 20350424
[TBL] [Abstract][Full Text] [Related]
31. The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia.
Karakas T; Miething CC; Maurer U; Weidmann E; Ackermann H; Hoelzer D; Bergmann L
Leukemia; 2002 May; 16(5):846-54. PubMed ID: 11986946
[TBL] [Abstract][Full Text] [Related]
32. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
33. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
[TBL] [Abstract][Full Text] [Related]
34. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
35. [Expression of Aurora Family Genes in Acute Leukemia and Its Clinical Significance].
Liu ZL; Xing Y; Li T; Wang C; Liu SF; Zhao HY; Zhang RH; Ma YJ; Zhang XY; Tian WL; Liu L; Sun H; Sun L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):334-339. PubMed ID: 28446271
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Pyo JS; Kang G; Kim JY
Int J Biol Markers; 2017 Mar; 32(1):e68-e74. PubMed ID: 27470134
[TBL] [Abstract][Full Text] [Related]
37. [Detection and evaluation of bcl-x and bcl-2 gene expression in blasts from patients with acute leukemia].
Shen X; Wang C; Qiao Z
Zhonghua Xue Ye Xue Za Zhi; 1999 Jul; 20(7):350-3. PubMed ID: 11721430
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 expression in acute myelogenous leukemia: the relation to myeloid antigen expression and response to therapy in Iranian patients.
Daneshbod Y; Amirghofran Z; Tabei SZ
Neoplasma; 2005; 52(2):109-14. PubMed ID: 15800708
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
